查詢結果分析
來源資料
相關文獻
- 淺析修格蘭氏症候群
- Glomerulonephritis and Pulmonary Involvement in a Patient with Primary Sjogren's Syndrome
- 原發性修格蘭氏症候群:認知與早期診斷之重要性
- 渴望甘霖的身體--乾燥綜合症(修格蘭氏症候群)
- 國人自體免疫疾病與深部靜脈栓塞和肺栓塞的關聯性
- 修格蘭氏症候群(Sjogren's Syndrome, SS)的中醫診療
- Life-threatening Hemoptysis as Initial Presentation of Primary Sjögren's Syndrome: A Case Report
- 中西醫結合治療修格蘭氏症候群併發吞嚥困難聲嘶病例
- 修格蘭氏症候群患者的口腔照護
- Increased Risk of Depression in Patients with Primary Sjogren's Syndrome: A Nationwide Cohort Study in Taiwan
頁籤選單縮合
題名 | 淺析修格蘭氏症候群=Sjögren's Syndrome |
---|---|
作者 | 郭廷濠; | 書刊名 | 藥學雜誌 |
卷期 | 34:4=137 2018.12[民107.12] |
頁次 | 頁58-63 |
分類號 | 415.695 |
關鍵詞 | 修格蘭氏症候群; 乾燥症狀; Sjögren's syndrome; 2016ACR/EULAR; |
語文 | 中文(Chinese) |
中文摘要 | 修格蘭氏症候群為一進展性自體免疫疾病,特徵為淋巴球浸潤破壞腺體造成乾燥 症狀,目前自體免疫上皮炎是其致病機轉的主流理論,即上皮細胞成為一非典型之抗 原呈現細胞,持續大量表現 TLR3受體使上皮細胞成為自體免疫反應的調節中心。由 於致病機轉逐漸明瞭與臨床試驗需求,2016年版之 ACR/EULAR 分類準則提出,除了 現行使用的藥物 (pilocarpine 與 cevimeline 等) 外,將有更多的生物製劑得以使用於治 療修格蘭氏症候群。 |
英文摘要 | Sjögren's syndrome(SS) is a progressive autoimmune-related disease. Destruction of gland function by lymphocytes infiltration result in sicca symptoms. To date, the most support theory is ‘autoimmune epithelitis’. That is, epithelial cells act as atypical antigenpresenting cell and constantly express TLR3 let themself become central regulators. The 2016 ACR/ EULAR classification criteria are applied because of more understanding about the pathophysiology of SS, and needing for conducting clinical trials. Not only current treatment (pilocarpine and cevimeline), but novel biological therapies will be available in the future. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。